The global pharmaceutical and biotechnology industry continued to witness strong dealmaking momentum in June 2026, with companies pursuing acquisitions, licensing agreements, research collaborations and strategic partnerships to strengthen pipelines, expand technology capabilities and accelerate access to innovative t…
Pharmaceutical companies accelerated dealmaking across oncology, AI-powered drug discovery, rare diseases, advanced therapies and manufacturing, with Pfizer, Lilly, Roche, Gilead, Biogen, Bristol Myers Squibb and several CDMOs leading strategic acquisitions, partnerships and licensing agreements. The global pharmaceu…
April 2026 Pharma Deals Roundup: Big-Ticket Acquisitions, AI Collaborations, and Cell Therapy Alliances Reshape Industry Landscape April 2026 delivered a robust wave of pharmaceutical deal-making, spanning multi-billion-dollar acquisitions, next-generation therapy collaborations, and AI-driven partnerships. The month…
From Otsuka’s $1.2 billion acquisition of Transcend Therapeutics to Novartis’ $12 billion buyout of Avidity Biosciences, the global pharmaceutical industry is witnessing a surge in high-value deals, AI-driven collaborations, and manufacturing alliances. These developments highlight a strong shift toward precision medi…
Strategic collaborations, acquisitions, and technology alliances continued to reshape the pharmaceutical and life sciences ecosystem in February 2026. Companies across the drug discovery, diagnostics, manufacturing, and digital health landscape pursued partnerships to expand technological capabilities, strengthen rese…
January 2026 pharma deal activity highlights AI-powered R&D partnerships, biologics manufacturing expansion, precision mental health platforms, and strategic CDMO alliances reshaping innovation, delivery, and global supply chains. The first month of 2026 signals a decisive evolution in healthcare and life science…
December 2025 witnessed robust pharma and biopharma dealmaking, with acquisitions, licensing agreements and strategic collaborations spanning vaccines, biologics, rare diseases, radiopharmaceuticals, CDMO services and advanced manufacturing platforms. December 2025 closed the year on a high note for the global pharma…
November 2025 proved to be one of the most strategically charged months for the pharmaceutical and biotech sector, driven by cross-border collaborations, oncology licensing and engineered platform integrations that will influence both pipeline velocity and commercial scale through 2026. Key global players scaled R&am…
October 2025 turned out to be a blockbuster month of strategic partnerships, billion-dollar acquisitions, and cross-border collaborations redefining how innovation scales in the post-pandemic biotech economy. From antibody-drug conjugates (ADCs) to RNA medicines, obesity drugs, and gene therapies, global giants and a…
The pharmaceutical and biotechnology sectors experienced a highly active September 2025, characterized by strategic licensing agreements, acquisitions, and partnerships across multiple therapeutic areas. Companies focused on portfolio expansion, precision medicine, advanced therapies, and operational optimization, sig…
Page 1 of 2